Amryt Raises 2021 Revenue Guidance - Quick Facts

Amryt (AMYT) said, given the strong performance of business year to date and recent acquisition of Chiasma, the company once again increased full year 2021 revenue guidance. For full year 2021, Amryt now projects revenue in a range of $220 million to $225 million which represents growth of 20%-23% from last year. The company's prior guidance was between $210 million - $215 million.

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT